Headlines about Galapagos NV (NASDAQ:GLPG) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Galapagos NV earned a daily sentiment score of 0.24 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.8853552925605 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media headlines that may have impacted Accern’s analysis:

Several research firms recently commented on GLPG. Zacks Investment Research raised Galapagos NV from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a report on Friday, July 14th. Stifel Nicolaus raised Galapagos NV from a “hold” rating to a “buy” rating and increased their target price for the company from $83.00 to $101.00 in a report on Friday. TheStreet raised Galapagos NV from a “d+” rating to a “c” rating in a report on Wednesday, May 17th. BTIG Research reissued a “buy” rating and issued a $98.00 target price on shares of Galapagos NV in a report on Tuesday, June 20th. Finally, Nomura increased their target price on Galapagos NV from $108.00 to $124.00 and gave the company a “buy” rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $96.14.

Galapagos NV (NASDAQ GLPG) opened at 83.73 on Friday. Galapagos NV has a one year low of $52.50 and a one year high of $94.88.

ILLEGAL ACTIVITY WARNING: “Galapagos NV (GLPG) Given Daily Coverage Optimism Score of 0.24” was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/galapagos-nv-glpg-given-daily-coverage-optimism-score-of-0-24/1477060.html.

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Insider Buying and Selling by Quarter for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.